Heat Biologics begins dosing patients in Phase I/II bladder cancer trial of HS-410
HS-410 is designed to activate a T-cell mediated pan-antigen immune response for the treatment of bladder cancer. Dosing in the Phase I/II trial was initiated by clinical investigator
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.